What Does Nemifitide diTFA Mean?
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To judge multiple intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Key demo targets had been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis suffere